A bladder cancer–associated gene signature for exploratory qPCR-based survival stratification in NAC-Treated muscle-invasive bladder cancer
4 affiliations
- 1Department of Urology, Cedars-Sinai Medical Center
- 2Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center
- 3Department of Urologic Sciences, University of British Columbia
- 4Department of Biomedical Science, Cedars-Sinai Medical Center
Abstract
Background Muscle-invasive bladder cancer (MIBC) is an aggressive and heterogeneous malignancy with limited biomarkers to guide patient stratification and response to neoadjuvant chemotherapy (NAC). We sought to define the biological basis and clinical utility of a bladder cancer–associated ten-gene signature for predicting prognosis and therapeutic response. Methods Bulk transcriptomic data from The Cancer Genome Atlas (TCGA) and single-nucleus RNA sequencing (snRNASeq) of primary MIBC tumors were integrated to characterize the cellular context of the ten-gene bladder cancer (BLCA) signature. Machine-learning approaches were applied to qPCR-derived expression data to develop an exploratory model for survival stratification. Results An expression-based direction-weighted BLCA signature score was associated with worse OS, DSS, and PFI in TCGA-BLCA and marked a tumor state characterized by coordinated activation of oncogenic programs including EMT, cell-cycle, and MAPK/PI3K signaling. snRNASeq revealed enrichment of signature activity within the stromal compartment, marked by expansion of FAP+ /PDPN+ fibroblasts and MHCII+ macrophages with endothelial remodeling. High-signature tumors exhibited an immune-dysregulated microenvironment characterized by increased immune checkpoint expression (CD274, HAVCR2, TIGIT) and reduced antigen-presentation machinery. This stromal-dominant phenotype was particularly associated with Luminal MIBC. Functionally, high expression of key signature components (e.g. SDC1, VEGFA, CXCL8) predicts a distinct, targetable vulnerability to MEK inhibitors in drug sensitivity databases. Conclusions Translating these findings, qPCR-derived expression of the ten-gene panel was used to build an exploratory machine-learning model for survival stratification in the NAC-treated MIBC cohort. The selected StepCox (forward) + RSF model showed moderate internal discrimination after bootstrap optimism correction (optimism-corrected C-index = 0.695, 95% CI 0.628–0.792), supporting the feasibility of qPCR-based risk modeling while highlighting the need for external validation.
Related
- Preoperative CRP–Albumin–Lymphocyte (CALLY) Index Is Associated with Survival but Does Not Predict Anastomotic Leak or Major Morbidity After Minimally Invasive Esophagectomy
- MetALD in Clinical Practice: Diagnosis, Non-Invasive Risk Stratification, and Management
- Precision risk stratification for perioperative safety of minimally invasive versus open TLIF in elderly patients with lumbar degenerative disease
- Minute-Scale Sleep-Onset HRV as a Candidate Risk-Stratification Biomarker for Diabetic Retinopathy: An Exploratory Pilot Study
- Postdiagnostic pretreatment risk stratification for chondrosarcoma survival using routinely available registry variables: a SEER-based temporal validation study
BibTeX
@article{chen2026bladder,
title = {{A bladder cancer–associated gene signature for exploratory qPCR-based survival stratification in NAC-Treated muscle-invasive bladder cancer}},
author = {Xingyu Chen and Toru Sakatani and Sunao Tanaka and Alberto Contreras-Sanz and Peter Black and Charles J. Rosser and Hideki Furuya},
journal = {Journal of Translational Medicine},
year = {2026},
month = jul,
doi = {10.1186/s12967-026-08681-2},
url = {https://doi.org/10.1186/s12967-026-08681-2},
note = {CC BY},
}
RIS
TY - JOUR
TI - A bladder cancer–associated gene signature for exploratory qPCR-based survival stratification in NAC-Treated muscle-invasive bladder cancer
AU - Xingyu Chen
AU - Toru Sakatani
AU - Sunao Tanaka
AU - Alberto Contreras-Sanz
AU - Peter Black
AU - Charles J. Rosser
AU - Hideki Furuya
PY - 2026
DA - 2026/07/01
JO - Journal of Translational Medicine
DO - 10.1186/s12967-026-08681-2
UR - https://doi.org/10.1186/s12967-026-08681-2
AB - Background Muscle-invasive bladder cancer (MIBC) is an aggressive and heterogeneous malignancy with limited biomarkers to guide patient stratification and response to neoadjuvant chemotherapy (NAC). We sought to define the biological basis and clinical utility of a bladder cancer–associated ten-gene signature for predicting prognosis and therapeutic response. Methods Bulk transcriptomic data from The Cancer Genome Atlas (TCGA) and single-nucleus RNA sequencing (snRNASeq) of primary MIBC tumors were integrated to characterize the cellular context of the ten-gene bladder cancer (BLCA) signature. Machine-learning approaches were applied to qPCR-derived expression data to develop an exploratory model for survival stratification. Results An expression-based direction-weighted BLCA signature score was associated with worse OS, DSS, and PFI in TCGA-BLCA and marked a tumor state characterized by coordinated activation of oncogenic programs including EMT, cell-cycle, and MAPK/PI3K signaling. snRNASeq revealed enrichment of signature activity within the stromal compartment, marked by expansion of FAP+ /PDPN+ fibroblasts and MHCII+ macrophages with endothelial remodeling. High-signature tumors exhibited an immune-dysregulated microenvironment characterized by increased immune checkpoint expression (CD274, HAVCR2, TIGIT) and reduced antigen-presentation machinery. This stromal-dominant phenotype was particularly associated with Luminal MIBC. Functionally, high expression of key signature components (e.g. SDC1, VEGFA, CXCL8) predicts a distinct, targetable vulnerability to MEK inhibitors in drug sensitivity databases. Conclusions Translating these findings, qPCR-derived expression of the ten-gene panel was used to build an exploratory machine-learning model for survival stratification in the NAC-treated MIBC cohort. The selected StepCox (forward) + RSF model showed moderate internal discrimination after bootstrap optimism correction (optimism-corrected C-index = 0.695, 95% CI 0.628–0.792), supporting the feasibility of qPCR-based risk modeling while highlighting the need for external validation.
SN - 1479-5876
ER -